PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 LEVEL ASSESSMENT IN METABOLIC SYNDROME PATIENTS WITH HEART FAILURE
https://doi.org/10.15829/1728-8800-2017-6-82-86
Abstract
Aim. To assess the level of galectin-3 in blood serum of metabolic syndrome patients (MS), with heart failure (CHF).
Material and methods. Totally, 43 patients investigated, with MS, and of those 37 CHF patients and 33 on-CHF, of those 17 had CHF diagnosed. Galectin-3 level in blood serum was measured by immune enzyme assay.
Results. Galectin-3 level in blood plasma of MS patients was significantly higher comparing to the group with no MS — 1,89±1,71 ng/mL and 1,03±0,22 ng/mL, respectively. In the control group maximum galectin-3 level was 1,5 ng/mL, but in MS group 27% had galectin-3 higher than 3 ng/mL. It was found that mean levels of galectin-3 were significantly higher in CHF group (1,73±1,59 ng/mL) comparing to non-CHF (1,05±0,26 ng/mL).
Conclusion. Level of galectin-3 in MS patients is higher than in those non-MS, but in MS and CHF galectin-3 concentration is higher than nonCHF. Further elaboration on this relationship might be useful in improvement of CHD and MS diagnostics.
About the Authors
O. M. Drapkina
National Research Center for Preventive Medicine of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
R. N. Shepel
National Research Center for Preventive Medicine of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
T. A. Deeva
I.M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Bazaeva EV, Myasnikov RP, Metelskaya VA, Boytsov SA. Diagnostic significance of biological markers in chronic heart failure with preserved left ventricular ejection fraction. Russian Heart Failure Journal. 2015; 1(88): 43-51. Russian (Базаева Е.В., Мясников Р.П., Метельская В.А., Бойцов С.А. Диагностическая значимость биологических маркёров при хронической сердечной недостаточности с сохранённой фракцией выброса левого желудочка. Сердечная Недостаточность. 2015; 1(88): 43-51).
2. Drapkina OM, Shepel RN. Telomeres and chronic heart failure. Cardiology. 2014; 54 (4): 60-67. Russian (Драпкина О.М., Шепель Р.Н. Теломеры и хроническая сердечная недостаточность. Кардиология. 2014; 54(4): 60-67).
3. Zimmet P, Shaw J, Alberti KG. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med. 2003; 20(9): 693-702.
4. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol, 2008;. e17-e39.
5. Fortuna-Costa A, Gomes AM, Kozlowski EO, et al. Extracellular galectin-3 in tumor progression and metastasis. Front Oncol, 2014; 4:138.
6. Iacobini C, Amadio L, Oddi G, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol, 2003; 14:S264-70.
7. Jiang JX, Chen X, Hsu DK, et al. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol, 2012; 302: G439-46
8. Lok DJ., Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol, 2010; 99:323-8.
9. de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail, 2009; 11:811-7.
10. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 2004; 110:3121-8.
11. Alberti KGMM, Zimmet PZ, Shaw JE The Metabolic Syndrome – а new worldwide definition from the International Diabetes Federation Consensus. Lancet, 2005; 366:1059-62.
12. Lin HM, Moon BK, Yu F, Kim HR. Galectin– 3 mediates genisteininduced G(2)/M arrest and inhibits apoptosis. Carcinogenesis, 2000; 21:1941– 1945.
13. Bazaeva EV, Myasnikov RP, Metelskaya VA, Boytsov SA. Diagnostic value of biochemical markers in patients with chronic heart failure with reduced, borderline and preserved left ventricular ejection fraction . Cardiology. 2017; 57(3): 39-45. Russian (Базаева Е.В., Мясников Р.П., Метельская В.А., Бойцов С.А. Диагностическая значимость биохимических маркеров при хронической сердечной недостаточности со сниженной, пограничной и сохраненной фракцией выброса левого желудочка. Кардиология, 2017; 57(3): 39-45).
14. Ionin VA, Listopad OV, Nifontov SE, i dr. Galektin- 3 in patients with metabolic syndrome and atrial fibrillation. Hypertension 2014; 5: 49- 83. Russian (Ионин В.А., Листопад О.В., Нифонтов С.Е., и др. Галектин– 3 у пациентов с метаболическим синдромом и фибрилляцией предсердий. Артериальная гипертензия 2014; 5: 49– 83).
15. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A, et al. Increased levels of galectin– 3 were associated with prediabetes and diabetes: new risk factor? Journal of Endocrinological Investigation 2014; 38(5):1–7.
16. Drapkina OM, Dubolazova JuV. Characteristics of pulse wave c in patients with arterial hypertension and heart failure with preserved ejection fraction. Russian Medical News 2012; 17 (4): 20-31. Russian (Драпкина О.М., Дуболазова Ю.В. Характеристики пульсовой волны у пациентов c артериальной гипертензией и сердечной недостаточностью с сохраненной фракцией выброса. Российские Медицинские Вести 2012; 17(4): 20-31).
17. De Boer RA, Voors AA, Muntendam P, et al. Galectin– 3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail, 2009; 11:811-817.
18. Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin– 3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin. Chim. Acta, 2009; 409: 96–99.
19. Lakomkin SV, Skvorcov AA, Gorjunova TV, i dr. Galectin-3 - a new marker of diagnosis and prognosis of chronic heart failure. Cardiology 2012; 3: 45-52. Russian (Лакомкин С.В., Скворцов А.А., Горюнова Т.В., Масенко В.П., Терещенко С.Н. Галектин-3 – новый маркер диагностики и прогноза хронической сердечной недостаточности. Кардиология 2012; 3: 45-52).
20. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013;62: e147-e239.
Review
For citations:
Drapkina O.M., Shepel R.N., Deeva T.A. PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 LEVEL ASSESSMENT IN METABOLIC SYNDROME PATIENTS WITH HEART FAILURE. Cardiovascular Therapy and Prevention. 2017;16(6):82-86. (In Russ.) https://doi.org/10.15829/1728-8800-2017-6-82-86
Views:
807
Email this article 
